Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of ALS-4 (IM032) Administered Orally to Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALS 4 (Primary)
Indications Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Aptorum Group

15 Mar 2022 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT05274802).
10 Jan 2022 Status changed from recruiting to completed, According to an Aptorum Group media release.
10 Jan 2022 According to an Aptorum Group media release, the company announces completion of the Phase I clinical trial for ALS-4.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com